Updates from the 2023 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 318 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…
ASH 2023: Increased Metabolism in High IRF4-Expressing Lymphoma Cells Limits the Availability of Glucose in the Tumor Microenvironment Cancer cells routinely reprogram cellular metabolism to improve their fitness, providing a selective advantage that supports growth and expansion. Researchers previously determined…
ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-Cell Therapies The treatment landscape of large B-cell lymphomas (LBCL) has changed dramatically in recent years, driven in part…
ASH 2023: Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma Treatment options for relapsed or refractory peripheral T-cell lymphoma (PTCL) are limited, and many patients experience an aggressive disease course. In the phase 2 VALENTINE-PTCL01 study,…
ASH 2023: Overall Survival in Mantle Cell Lymphoma Has Improved in the Era of Targeted Therapies Mantle cell lymphoma (MCL) has historically been treated using combination chemoimmunotherapy followed by stem cell transplant and has been associated with poor survival outcomes.…
ASH 2023: High Complete Response Rates in High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Loncastuximab Tesirine Loncastuximab tesirine is an antibody-drug conjugate that has demonstrated synergistic properties when used in combination with rituximab. Interim results from an ongoing phase 2 study…
ASH 2023: Total Lifetime Costs of Treating Chronic Lymphocytic Leukemia are High Treatment advances in chronic lymphocytic leukemia (CLL) have improved outcomes for people living with this disease. Relapses remain common, though, and people with CLL often receive multiple lines…
ASH 2023: Barriers Identified to the Use of CAR T-cell Therapy in Non-Hodgkin Lymphoma While chimeric antigen receptor (CAR) T-cell therapy represents a promising treatment option for patients with non-Hodgkin lymphoma (NHL), many community physicians face challenges that make it…
ASH 2023: MRD Status Predicts Progression-free Survival Outcomes in Follicular Lymphoma The disease course in follicular lymphoma (FL) is highly variable, and it is currently difficult to predict which patients will experience long, durable responses and who will relapse quickly…
